Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

The Business Cocktail

The Business Cocktail

Mar 21, 2019

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million

GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review
voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug
Administration programme to accelerate speedy recovery of rare disease. GW received the voucher
when FDA approved its cannabinoid medicine Epidiolex for treating seizures.

BioMed Realty acquires Emeryville Center for Innovation

BioMed Realty-a blackstone portfolio company has acquired Emeryville Center for Innovation for USD
135 million. This campus acquisition of around 250,000 square foot, six-story life science office building
will help BioMed to dominate the market of Life Sciences in San Francisco.

Merck, Iktos to explore AI for drug discovery

Merck, a leading science and technology company has decided to use its generative modelling artificial
intelligence (AI) technology to facilitate the rapid and cost-effective discovery and design of promising
new compounds in collaboration with Iktos’ AI technology.

Merck, and GenScript for Cell and Gene Therapy in China

Merck among the only few to industrialize the process of making viral vectors has now announced its
decision to commercialize the Cell and Gene therapy in collaboration with GenScript- a China biotech
company. Merck will extend its support in processing products, services and staff training to GenScript
to accelerate the manufacturing of plasmids and viral vectors.

Downloads

Article in PDF

Recent Articles
  1. Virus, the Cancer Therapy of the Future
  2. Navigating the Healthcare Horizon: Odyssey of Mergers, Funding, and Acquisitions in 2024
  3. Merck and Moderna Initiate Study to Evaluate V940; FDA Approves Vertex and CRISPR Therapeutics’ C...
  4. Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raises
  5. AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes
pharma-news-for-regeneron-astrazeneca-syndax
Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves PTC’s AADC Gene Therapy; DUPIXENT sBLA Acceptance for Urticaria; CHMP Recommends TAGRISSO for EGFR Lung Cancer; FDA Approves DANZITEN for CML; Syndax Wins FDA Approval for REVUFORJ in Acute Leukemia

cell-and-gene-therapy-for-parkinsons-disease-treatment
Articles

The Future of Parkinson’s Disease Treatment: Unlocking the Potential of Cell and Gene Therapy

Pharma-news-for-autolus-unicycive-abbvie
Notizia - Recent Pharma, Healthcare and Biotech Happenings

AUCATZYL Approved for R/R B-ALL; FDA Accepts NDA for Unicycive’s Oxylanthanum Carbonate; AstraZeneca and Amgen Report Positive Results in Chronic Rhinosinusitis; Nipocalimab Granted Breakthrough Designation for Sjögren’s Disease; AbbVie’s Schizophrenia Drug Fails Phase Studies

AI
Artificial technology
Biohaven
BioMed Realty
Blackstone
cannabinoid
cell therapy
China
drug discovery
Emeryville Center of Innovation
Epidiolex
FDA
Gene therapy
GenScript
GW Pharmaceuticals
Iktos
Merck
Plasmid
PRV
Rare Disease
San Francisco
Seizures
USD
viral vector
loader